ArticlePloS one2012
Cancer-associated carbohydrate antigens as potential biomarkers for hepatocellular carcinoma.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 51 citations in OpenAlex.
- Serum antibody screening using glycan arrays.Chemical Society reviews · 2024Review
- AB Toxins as High-Affinity Ligands for Cell Targeting in Cancer Therapy.International journal of molecular sciences · 2023Review
- Disialoganglioside GD2-Targeted Near-Infrared Photoimmunotherapy (NIR-PIT) in Tumors of Neuroectodermal Origin.Pharmaceutics · 2022Article
- Update on Glycosphingolipids Abundance in Hepatocellular Carcinoma.International journal of molecular sciences · 2022Review
- Cancer-Associated Glycosphingolipids as Tumor Markers and Targets for Cancer Immunotherapy.International journal of molecular sciences · 2021Review
- Heparanase (HPSE) gene polymorphism (rs12503843) contributes as a risk factor for hepatocellular carcinoma (HCC): a pilot study among Egyptian patients.Journal, genetic engineering & biotechnology · 2021Article
- Better survival is observed in cervical cancer patients positive for specific anti-glycan antibodies and receiving brachytherapy.Gynecologic oncology · 2020Article
- Prognostic potential of the preoperative plasma complement factor B in resected pancreatic cancer: A pilot study.Cancer biomarkers : section A of Disease markers · 2019Article
- IgG Antibodies to GlcNAcDisease markers · 2018Article
- Article
- Factors Affecting Anti-Glycan IgG and IgM Repertoires in Human Serum.Scientific reports · 2016Article
- Article
- Fibroblast growth factor receptor 4 polymorphism is associated with liver cirrhosis in hepatocarcinoma.PloS one · 2015Article
- Vitamin C enhances anticancer activity in methotrexate‑treated Hep3B hepatocellular carcinoma cells.Oncology reports · 2014Article
- TIMP-3 -1296 T>C and TIMP-4 -55 T>C gene polymorphisms play a role in the susceptibility of hepatocellular carcinoma among women.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Association of novel gene polymorphisms RRM1 -756T>C and -269 C>A with breast cancer.Journal of clinical laboratory analysis · 2014Article
- Dual role of acetaminophen in promoting hepatoma cell apoptosis and kidney fibroblast proliferation.Molecular medicine reports · 2014Article
- Role of VEGF-C gene polymorphisms in susceptibility to hepatocellular carcinoma and its pathological development.Journal of clinical laboratory analysis · 2014Article
- Glabridin mediate caspases activation and induces apoptosis through JNK1/2 and p38 MAPK pathway in human promyelocytic leukemia cells.PloS one · 2014Article
- Impact of EZH2 polymorphisms on urothelial cell carcinoma susceptibility and clinicopathologic features.PloS one · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is one of the most common human malignancies. Therefore, developing the early, high-sensitivity diagnostic biomarkers to prevent HCC is urgently needed. Serum a-fetoprotein (AFP), the clinical biomarker in current use, is elevated in only ~60% of patients with HCC; therefore, identification of additional biomarkers is expected to have a significant impact on public health. In this study, we used glycan microarray analysis to explore the potential diagnostic value of several cancer-associated carbohydrate antigens (CACAs) as biomarkers for HCC. We used glycan microarray analysis with 58 different glycan analogs for quantitative comparison of 593 human serum samples (293 HCC samples; 133 chronic hepatitis B virus (HBV) infection samples, 134 chronic hepatitis C virus (HCV) infection samples, and 33 healthy donor samples) to explore the diagnostic possibility of serum antibody changes as biomarkers for HCC. Serum concentrations of anti-disialosyl galactosyl globoside (DSGG), anti-fucosyl GM1 and anti-Gb2 were significantly higher in patients with HCC than in chronic HBV infection individuals not in chronic HCV infection patients. Overall, in our study population, the biomarker candidates DSGG, fucosyl GM1 and Gb2 of CACAs achieved better predictive sensitivity than AFP. We identified potential biomarkers suitable for early detection of HCC. Glycan microarray analysis provides a powerful tool for high-sensitivity and high-throughput detection of serum antibodies against CACAs, which may be valuable serum biomarkers for the early detection of persons at high risk for HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.